Catalog No. |
TD-VK421046 |
Description |
Felvizumab [HuRSV19VHFNS/VK, RSHZ19, RSV monoclonal antibody, SB209763] is a humanised monoclonal antibody (IgG1) prepared by the humanization of an F protein-specific murine MAb. In in vitro studies, palivizumab, another humanized Mab specific for the F protein of RSV, was 4 to 5-fold more potent than felvizumab in neutralising RSV (Scott, 1999). |
Species reactivity |
HRSV-A |
Applications |
Research Grade Biosimilar |
Host species |
Humanized |
Isotype |
IgG1, kappa |
Expression system |
Mammalian Cells |
Clonality |
Monoclonal |
Target |
F, Fusion glycoprotein F0, Fusion glycoprotein F2, p27, Intervening segment, Pep27, Peptide 27, Fusion glycoprotein F1 |
Endotoxin level |
Please contact the lab for this information. |
Purity |
>95% purity as determined by SDS-PAGE. |
Purification |
Protein A/G, purified from cell culture supernatant. |
Accession |
P03420 |
Form |
Liquid |
Storage buffer |
0.01M PBS,pH7.4. |
Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
Alternate Names |
SB209763,HuRSV19VHFNS/VK,RSHZ19monoclonalantibody,SB209763,CAS:167747-20-8 |
Background |
Felvizumab is a humanized monoclonal antibody against respiratory syncytial virus. |
Note |
For research use only. Not for use in clinical or therapeutic applications. |